Scarica l'app Stockscreener
3.79
3.81%
-0.15
Dopo l'orario di chiusura:
3.86
0.07
+1.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - Stock Titan
CT drugmaker partners on development of inhaled weight-loss treatment - hartfordbusiness.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind inks obesity deal with Rose Pharma - The Pharma Letter
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga
MannKind signs global GLP-1 inhalation collaboration deal - grafa.com
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - finance.yahoo.com
MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growth Concerns - GuruFocus
MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India
MannKind partners with Rose Pharma on inhaled GLP-1 therapy - Investing.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times
MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative
A rapid-acting, short-duration inhaled treatment is being developed for weight management - Stock Titan
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind to Present at Upcoming Investor Conferences - The Manila Times
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering - Kalkine Media
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares - Stock Titan
MannKind files legal opinion for common stock offering under shelf registration - TradingView
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story - simplywall.st
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat
MannKind gains FDA approvals, boosting growth p... - Pluang
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK
Mannkind director Steven Binder sells $158,547 in common stock - Investing.com India
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares - GuruFocus
Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD - MarketBeat
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD - MarketBeat
Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD - marketbeat.com
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale - Stock Titan
Danbury biopharma company expands workforce, manufacturing amid new product launches - Hartford Business Journal
MannKind (NASDAQ:MNKD) Upgraded by Zacks Research to Hold Rating - MarketBeat
Empowered Funds LLC Invests $1.88 Million in MannKind Corporation $MNKD - MarketBeat
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 By Investing.com - Investing.com South Africa
MNKD Maintained by Wells Fargo -- Price Target Lowered to $13.00 - GuruFocus
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says - Yahoo Finance
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 - Investing.com
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts Drive Growth - GuruFocus
MannKind Q2 Earnings Call Highlights - marketbeat.com
MNKD SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results - MarketBeat
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):